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Abstract
Introduction: Ultrasonography (US) has better sensitivity than clinical evaluation for the detection of synovitis in early 
rheumatoid arthritis (RA). Patients presenting with arthralgia and a positive anti-citrullinated protein antibodies (ACPA) 
and/or Rheumatoid Factor (IgM-RF) status are at risk for developing RA. In the present study, US utility and predictive 
properties in arthralgia patients at risk for the development of arthritis were studied.
Methods: 192 arthralgia patients with ACPA and/or IgM-RF were included. Absence of clinical arthritis was confirmed 
by two physicians. US was performed by one of two trained radiologists of any painful joint, and of adjacent and 
contralateral joints. Joint effusion, synovitis and power Doppler (PD) signal in the synovial membrane of the joints and 
tenosynovitis adjacent to the joint were evaluated and classified on a 4-grade semi-quantitative scale. Grade 2-3 joint 
effusion, synovitis, tenosynovitis and grade 1-3 Power Doppler signal were classified as abnormal.
Results: Forty-five patients (23%) developed arthritis after a mean of 11 months. Inter-observer reliability for synovitis 
and PD was moderate (kappa 0.46, and 0.56, respectively) and for joint effusion low (kappa 0.23). The prevalence of 
tenosynovitis was too low to calculate representative kappa values. At joint level, a significant association was found 
between US abnormalities and arthritis development in that joint for joint effusion, synovitis and PD. At patient level, a 
trend was seen towards more arthritis development in patients who had US abnormalities for joint effusion, synovitis, 
PD and tenosynovitis.
Conclusions: US abnormalities were associated with arthritis development at joint level, although this association did 
not reach statistical significance at patient level. US could potentially be used as a diagnostic tool for subclinical arthritis 
in seropositive arthralgia patients. However, further research is necessary to improve test characteristics.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease resulting in joint damage. The presence of auto-anti-
bodies such as anti-citrullinated protein antibodies
(ACPA) and/or immunoglobulin M-rheumatoid factor
(IgM-RF) is a characteristic finding in RA. These auto-
antibodies can often be detected years before the onset of
clinical disease and can predict the development of
arthritis [1-3]. Concomitant arthralgia appears to
increase the risk of developing arthritis even further [3]
and thus seropositive arthralgia patients could be consid-
ered as preclinical RA patients. This phase of the disease
is of interest now that evidence supports very early inter-
vention in RA [4]. Treating even earlier in the preclinical
phase may prevent progression to RA. However, a sub-
stantial part of seropositive arthralgia patients does not
develop arthritis [3] and it remains a challenge to separate
true preclinical RA patients from plain arthralgia
patients.
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Ultrasonography (US) is a promising tool for use in the
diagnosis of arthritis because it is relatively cheap, multi-
ple joints can be examined in a short period of time and
bo ne  st ruct ur e  as we l l as  soft  t is su e  can be  e xa m ined.
Moreover, US has a better sensitivity than physical exam-
ination in the detection of synovitis in early arthritis and
RA [5]. In a recent study of patients with morning stiff-
ness of at least one hour with or without clinical arthritis,
the presence of US abnormalities in hand joints increased
the probability of later inflammatory arthritis, although
only in the subgroup of seronegative patients. All sero-
positive patients developed arthritis and thus there was
no additional value of US in these patients [6]. The pres-
ent study concerns seropositive arthralgia patients alone,
of whom a substantial part did not develop arthritis [3].
US utility and predictive properties were studied in this
cohort.
Materials and methods
Study population
Between August 2004 and August 2008, arthralgia
patients with a positive ACPA and/or IgM-RF status were
recruited at rheumatology clinics in the Amsterdam area
of the Netherlands after referral by a general practitioner.
Patients without arthritis, but with a positive ACPA and/
or IgM-RF status were referred for inclusion in the pres-
ent study. Arthralgia was defined as non-traumatic pain
in any joint. Absence of arthritis was independently con-
firmed by physical examination of 44 joints [7] by a
trained medical doctor (WB or LAS) and a senior rheu-
matologist (DS). The latter was blinded for the patient's
history and laboratory results. ACPA and/or IgM-RF
were confirmed in a second sample. Patients with arthri-
tis as revealed by chart review or baseline physical exami-
nation, a negative ACPA and IgM-RF status on second
analysis, previous treatment with a disease-modifying
antirheumatic drug (DMARD) or recent glucocorticoid
treatment (<3 months) were excluded. In total, 192 arth-
ralgia patients (72% female, mean ± standard deviation
(SD) age 47.6 ± 11 years) with a positive ACPA and/or
IgM-RF status were included in the present study. Of
these patients, 70 were also included in a randomized pla-
cebo-controlled trial studying the effects of intramuscu-
lar dexamethasone on arthritis development. As
dexamethasone did not delay or prevent arthritis [8]
these patients were considered suitable for the present
analysis.
At baseline, medical history, details of joint complaints
and the number of tender joints at physical examination
of 53 joints were recorded [9]. During yearly follow-up
visits, development of arthritis in any of 44 joints [7] was
confirmed by two investigators (WB or LAS and DS).
Extra visits were planned if arthritis developed. Median
follow up was 26 months (range 6 to 54 months).
Nine healthy controls (7 women and 2 men; mean age
47.3 years, range 36 to 58 years) without signs or symp-
toms of arthritis as confirmed by clinical examination of
44 joints [9] and with a negative ACPA and IgM-RF status
were also studied.
This study was approved by the local ethics committee
and informed consent was given by all patients prior to
inclusion.
Ultrasonography
US was performed within a median of three weeks (inter-
quartile range (IQR) one to five weeks) after the first visit.
If present, tender joints at physical examination were
scanned, otherwise joints that were painful by history
were scanned. Furthermore, for proximal interphalangeal
(PIP), metacarpal phalangeal (MCP) and metatarsopha-
langeal (MTP) joints the directly adjacent joints in the
same joint group as the painful joints were scanned, for
example, in the case of a painful MCP3, MCP2 to 4 were
scanned. US was also performed on the contralateral
joints selected in this way. (As some patients had bilateral
joint complaints, contralateral joints could include pain-
ful joints.) Joints were scored on a four-grade semiquanti-
tative scale for joint effusion, synovitis, tenosynovitis and
power Doppler signal, as described before and explained
here [10].
Joint effusion was defined as a compressible anechoic
intracapsular area and scored as follows: 0 = no effusion,
1 = minimal amount of joint effusion, 2 = moderate
amount of joint effusion (without distension of the joint
capsule) and 3 = extensive amount of joint effusion (with
distension of the joint capsule). Synovitis was defined as a
noncompressible hypoechoic intracapsular area (synovial
thickening) and scored as follows: 0 = no synovial thick-
ening, 1 = minimal synovial thickening (filling the angle
between the periarticular bones, without bulging over the
line linking tops of the bones), 2 = synovial thickening
bulging over the line linking tops of the periarticular
bones but without extension along the bone diaphysis, 3
= synovial thickening bulging over the line linking tops of
the periarticular bones and with extension to at least one
of the bone diaphyses. Power Doppler signal was used to
display flow signal in the synovium and scored as follows:
0 = no flow in the synovium, 1 = single vessel signals, 2 =
confluent vessel signals in less than half of the area of the
synovium, 3 = vessel signals in more than half of the area
of the synovium [10]. Tenosynovitis was defined as
hypoechoic or anechoic thickened tissue with or without
fluid within the tendon sheath and scored as follows: 0 =
no thickened tissue, 1 = minimal thickening, 2 = moder-
ate thickening, 3 = extensive thickening.van de Stadt et al. Arthritis Research & Therapy 2010, 12:R98
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In the healthy controls, either MCP joint 2 to 4 and PIP
joint 2 and 3 (n = 3), MCP joint 3 to 5 and PIP joint 4 and
5 (n = 3), or MCP joint 2 to 4 and the wrist joint (n = 3)
were scanned. US was performed bilaterally.
In this study, grades 2 to 3 of joint effusion, synovitis
and tenosynovitis were regarded as abnormal, and grades
1 to 3 power Doppler signal was regarded as abnormal
[10,11].
All scans were performed with the Acuson Antares
ultrasound system, premium edition (Siemens, Malvern,
PA, USA) using linear array transducers VF 13-5 SP for
finger and toe joints, (operating at 11.43 MHz for grey-
scale and 8.9 MHz for PD) and VF 13-5 for larger joints
(operating at 11.43 MHz for greyscale and 7.3 MHz for
PD), according to the manufacturer's criteria. All joints
were scanned in the longitudinal plane from the most lat-
eral to most medial site and in the transverse plane from
the proximal to distal site of the joint.
The US examinations were performed by two indepen-
dent investigators (HW and MMR), both radiologists
with extensive experience in musculoskeletal US. The
investigators were blinded for clinical data. Healthy con-
trols were referred as if they were arthralgia patients.
Prior to the study, consensus was reached between the
investigators about scanning technique, pathology defini-
tions and scoring.
Interobserver reliability was evaluated by scanning 148
joints of 14 patients, including 7 patients fulfilling ACR
criteria of RA [12], successively by both investigators,
who were blinded for each other's findings and all other
study data.
Laboratory investigations
ACPA and IgM-RF levels were determined at baseline by
second-generation anti-cyclic citrullinated peptide (anti-
CCP) ELISA (Axis Shield, Dundee, UK) and in-house
ELISA as previously described [1].
Statistical analysis
Data evaluation and statistical analysis were performed
with SPSS version 16.0 software (SPSS Inc., Chicago, IL,
USA). Continuous data with Gaussian distribution were
summarized with mean and SD. Non-normally distrib-
uted data were summarized with median and IQR. Cate-
gorical data were analyzed by Chi-square test and results
were expressed as odds ratio (OR) with 95% confidence
interval (CI). Inter-observer agreement was calculated by
quadratic weighted kappa-statistics for the ordinal data.
After dichotomization of ordinal data as described above,
regular kappa values and overall agreement were calcu-
lated.
Results
Arthritis development
One hundred and ninety-two patients with mild to mod-
erate joint complaints were examined. Their baseline
characteristics are shown in Table 1. Of these patients, 45
(23%) developed arthritis in one or more joints after a
mean follow up of 11 (SD ± 9, range 1 to 41) months.
Their median tender joint count (of 53 joints) at the time
of arthritis development was 6 (IQR 3 to 10), while their
median swollen joint count (of 44 joints) was 3 (IQR 2 to
6). Arthritis development occurred mostly in the wrist,
and MCP, PIP and MTP joints (Figure 1). Of the 45
patients that developed arthritis, 22 (49%) had RA
according to the 1987 ACR criteria [12], and 23 (51%)
were diagnosed with undifferentiated arthritis (UA). Of
these 23 patients, 11 patients later developed RA, and 9
patients never fulfilled more than 3 ACR RA criteria and
remained UA patients. Three UA patients went into
spontaneous remission. The presence of pain in a joint at
physical examination at baseline was associated with
arthritis development in that joint (OR 3.2, 95% CI 1.8 to
5.9, P < 0.001), with a positive predictive value of 11% and
a negative predictive value of 96% (data not shown). This
association was also present when only the subgroup of
patients who developed arthritis was considered. Within
this group the presence of pain was associated with
arthritis development with an OR of 4.1 (95% CI 2.4 to
7.2, P < 0.001; Figure 2).
Table 1: Baseline characteristics
n = 192
Age in years, mean ± SD 47 ± 11
Female sex 138 (72%)
Arthralgia duration in months, 
median (IQR)
12 (9-36)
Number of reported painful joints, 
median (IQR)
2 (0-4)
Tender joint count (53 joints), 
median (IQR)
0 (0-1)
Antibody status
ACPA negative, IgM-RF positive 60 (31%)
ACPA positive, IgM-RF negative 71 (37%)
ACPA positive, IgM-RF positive 61 (32%)
ACPA, anti citrullinated protein antibodies; IQR, interquartile 
range; RF, rheumatoid factor; SD, standard deviation.van de Stadt et al. Arthritis Research & Therapy 2010, 12:R98
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Ultrasonography
Healthy controls
Eighty-four joints of nine healthy controls were exam-
ined. In one joint, grade 2 joint effusion was detected. In
18 joints (21%), grade 1 joint effusion was seen and in five
joints (6%) grade 1 synovitis was seen. No other US
abnormalities were detected.
Interobserver reliability
The two investigators performed double US of 148 joints
of 14 patients. For the presence of joint effusion, synovi-
tis, power Doppler signal and tenosynovitis, the interob-
server agreement showed a high overall agreement (88 to
92%). However, kappa values were low for the presence of
joint effusion and moderate for the presence of synovitis
and power Doppler (Table 2). For tenosynovitis, kappa
values could not be calculated due to very low prevalence.
Dichotomization of the outcome variables did not influ-
ence interobserver reliability for joint effusion or synovi-
tis and slightly reduced reliability for power Doppler.
US and arthritis development at joint level
US was performed on 1823 joints in total (1017 MCP, 252
PIP, 225 MTP, 316 wrist joints, 3 ankle and 10 knee
joints), of which 483 were joints of patients who devel-
oped arthritis. Of the joints in which US had been per-
formed, 78 (4.3% of the total or 16% of those with
arthritis) were swollen at the time of arthritis develop-
ment. In total 221 joints were swollen at the time of
arthritis development. The presence of pain in a joint at
physical examination at baseline was associated with the
presence of joint effusion, synovitis, or power Doppler
signal in that joint at baseline (OR 3.22, 4.77 and 7.08,
Figure 1 Arthritis development of individual joints. During yearly follow-up visits, development of arthritis in any of 44 joints was independently 
confirmed by two investigators. The percentage of all arthritic joints in which arthritis developed in that particular joint is shown. Grey bars represent 
the right sided joints, black bars the left sided joints. AC, acromioclavicular; IP, interphalangeal; MCP, metacarpal phalangeal; MTP, metatarsophalan-
geal; PIP, proximal interphalangeal; SC, sternoclavicular.
Figure 2 Association of pain at baseline with arthritis develop-
ment in joints of patients that developed arthritis. At baseline 53 
joints per patient were scored for the presence of pain at physical ex-
amination. At the time of arthritis development 44 joints were scored 
for the presence of soft tissue swelling at physical examination. Depict-
ed are the joints of patients that developed arthritis. Grey bars repre-
sent unaffected joints, black bars represent joints in which arthritis 
developed.van de Stadt et al. Arthritis Research & Therapy 2010, 12:R98
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respectively; Table 3). Moreover, the presence of joint
effusion, synovitis, or power Doppler signal in a joint was
associated with arthritis development in that joint (OR
3.07, 5.45 and 5.50, respectively; Table 4). Corresponding
positive predictive values were 12%, 18% and 18%, respec-
tively. The combination of the presence of synovitis and
power Doppler signal increased the risk for the develop-
ment of arthritis (OR 12.9) with a positive predictive
value of 35%. Prevalence of other combinations was too
low to calculate the corresponding risk (Table 4).
US and arthritis development at patient level
US was performed in 192 patients. The median number
of scanned joints was 8 (IQR 6 to 10), mainly MCP, PIP
and wrist joints. A positive trend was seen for the pres-
ence of joint effusion, synovitis, power Doppler signal, or
tenosynovitis in one or more joints at baseline and the
development of arthritis, although this did not reach sta-
tistical significance (Table 5).
Discussion
US utility and predictive properties in ACPA and/or IgM-
RF-positive arthralgia patients at risk for developing
arthritis, but without clinical arthritis, were studied. One-
quarter of the patients developed arthritis during follow
up and in this group a trend was seen towards more US
abnormalities at baseline than in the patients who did not
develop arthritis. Furthermore, at the joint level a signifi-
cant association of US abnormalities and the develop-
ment of arthritis in that joint was found. Although the
positive predictive values for arthritis development of US
abnormalities were moderate and only slightly better
than for pain at physical examination, the combination of
synovitis and power Doppler signal increased predictive
properties. Both synovitis and power Doppler signal were
better predictors than the presence of joint effusion and
the presence of power Doppler signal correlated better
with the presence of pain than grey scale US. These
results imply that US is able to detect subclinical arthritis
in patients that later develop arthritis and are in line with
previous studies that showed that US is more sensitive
than clinical examination [5]. The advantage of power
Doppler over other modalities has also been shown
before. It was more predictive than grey scale US for
relapse or radiographic progression in RA patients in
clinical remission [13,14].
There are some limitations to this study. First, the inter-
observer reliability was not optimal. Although overall
agreement was good, kappa values were low to moderate.
This could partly be explained by the nature of the stud-
ied population in which the prevalence of US abnormali-
ties is low and abnormalities, if present, have a low grade.
A low prevalence and the difficulty of the differentiation
of low-grade abnormalities from normal both decrease
interobserver reliability.
A second limitation is that the joints chosen for scan-
ning were selected based on the presence of pain at phys-
ical examination or as reported by the patient. Although
this resembles a clinical setting, this selection procedure
might not be optimal, because this results in different sets
of joints and total joint scores cannot be compared.
Table 2: Interobserver reliability
Weighted Kappa (95% CI)* Kappa (95% CI)† Overall agreement†
Joint effusion 0.22 (0.10-0.43) 0.23 (0.00-0.63) 92%
Synovitis 0.47 (0.23-0.70) 0.46 (0.24-0.67) 88%
Power Doppler 0.67 (0.46-0.91) 0.56 (0.34-0.77) 91%
Tenosynovitis ‡ ‡ 91%
* weighted kappa values were calculated for ordinal data, † kappa values and overall agreement were calculated for dichotomized data, ‡ 
kappa values could not be calculated, because one observer did not score any abnormalities.
CI, confidence interval.
Table 3: Association of pain at baseline with ultrasound abnormalities at baseline
Joints with Pain -
n = 1705
Pain +
n = 118
OR (95% CI)
Joint effusion grade 2-3 28 (1.6%)* 6 (5.1%) 3.22 (1.30-7.94)
Synovitis grade 2-3 29 (1.7%) 9 (7.6%) 4.77 (2.20-10.3)
Power Doppler grade1-3 34 (2.0%)† 15 (13%) 7.08 (3.73-13.4)
* n = 1696 (0.5% missing), †: n = 1686 (1% missing).
CI, confidence interval; OR, odds ratio.van de Stadt et al. Arthritis Research & Therapy 2010, 12:R98
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Finally, at the patient level only a trend was seen
towards more development of arthritis in patients that
showed US abnormalities. The fact that this trend did not
reach statistical significance can partly be explained by
low power. The results will need to be confirmed in fur-
ther studies with larger numbers of patients. On the other
hand, US abnormalities were detected in patients that did
not develop arthritis. These could be patients that will
develop arthritis in the future or abnormalities could
have been detected in patients with subclinical inflamma-
tion that subsided spontaneously. For clinical decision-
making, it is important to discriminate these two patient
categories from one another and thus specificity should
be increased. This might be achieved by repeating US
after a few months. Repeated US could also clarify
whether multiple joints show US abnormalities succes-
sively in these patients.
Another improvement could be the use of a standard-
ized US joint count with a defined set of joints. Together
with regular training sessions, this would probably
increase reliability [15]. A multiple joint scoring system
would be more time-consuming, but when only the joints
that are mostly afflicted by RA are chosen, this would
save time and could nevertheless result in higher sensitiv-
ity [5]. Furthermore, if such a system is able to reliably
predict arthritis development, it could be used in the
clinic to support treatment decisions. Various simplified
US joint count scoring systems have been evaluated in
patients with early and established RA that seem feasible
to assess joint inflammation in these patient groups
[16,17]. Such a scoring system will have to be validated
for patients presenting with arthralgia.
Alternatively, additional imaging techniques could be
used to study subclinical inflammation in seropositive
arthralgia patients. Magnetic resonance imaging and pos-
itron emission tomography scanning are playing an
increasingly important role in the investigation and man-
agement of RA [18]. These techniques could be useful on
their own or adjacent to US; their use is currently being
investigated in a subgroup of the present cohort.
Conclusions
US could become a promising diagnostic tool in patients
with seropositive arthralgia. It is associated with arthritis
development at the joint level and when more extensive
US scoring systems are used, it might be able to predict
arthritis development both at the patient and joint levels.
Further research is necessary to verify this.
Table 4: Association of ultrasound abnormalities with arthritis development at joint level
Joints with Arthritis -
n = 1745
Arthritis +
n = 78
OR (95% CI) PPV
Joint effusion grade 2-3 30 (1.7%) 4 (5.1%) 3.07 (1.05-8.94) 12%
Synovitis grade 2-3 31 (1.8%)* 7 (9%) 5.45 (2.32-12.8) 18%
PD grade 1-3 40 (2.3%)† 9 (11.5%) 5.50 (2.57-11.9) 18%
Synovitis and PD 11 (0.6%) 6 (7.7%) 12.9 (4.65-36.0) 35%
Joint effusion and synovitis 5 (0.3%) 0 na
Joint effusion and PD 6 (0.3%) 0 na
* n = 1735 (0.5% missing), † n = 1726 (1% missing), CI, confidence interval; na, not applicable due to low numbers; OR, odds ratio; PD, power 
Doppler; PPV, positive predictive value.
Table 5: Association of ultrasound abnormalities with arthritis development at patient level
# patient with ≥1 joint Arthritis -n = 147 Arthritis +n = 45 Arthritis +UA
n = 12
Arthritis +RA
n = 33
OR (95% 
CI)(Arthritis - vs. 
arthritis +)
Joint effusion grade 2-3 14 (10%) 8 (18%) 3 (25%) 5 (15%) 2.05 (0.80-5.27)
Synovitis grade 2-3 17 (12%) 7 (16%) 1 (8%) 5 (18%) 1.41 (0.54-3.65)
PD grade 1-3 23 (16%) 10 (22%) 1 (8%) 9 (27%) 1.54 (0.67-3.54)
Tenosynovitis grade 2-3 9 (6%) 4 (9%) 0 4 (12%) 1.50 (0.44-5.11)
CI, confidence interval; OR, odds ratio; PD, power Doppler; RA, rheumatoid arthritis; UA, undifferentiated arthritis.van de Stadt et al. Arthritis Research & Therapy 2010, 12:R98
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